Viva In Vitro Diagnostics

Viva In Vitro Diagnostics is a biomedical company focused on immunological medicine, particularly in developing innovative diagnostic solutions for sepsis and inflammatory diseases. Founded in 2021 as the first spin-off from the Instituto Murciano de Investigación Biosanitaria, the company aims to translate research on immune diseases into clinical applications that enhance patient outcomes. The flagship product, VIVA-ELISA®, is a patented diagnostic test that predicts the severity of sepsis before it becomes critical. This tool utilizes the NLRP3 inflammasome pathway to enable timely interventions, potentially reducing sepsis mortality by 25-40%. The technology has been clinically validated through studies involving over 500 patients in Spain and is pursuing regulatory approvals in the EU and the US. Additionally, Viva In Vitro is developing automated devices for hospital laboratories and is involved in projects targeting various sepsis conditions and inflammatory diseases. Viva In Vitro is dedicated to saving lives by advancing personalized medicine and has received multiple awards for its innovative contributions to healthcare. Its target customers include hospitals, clinical laboratories, and healthcare providers focused on improving patient care in critical settings.

• Employees 8
• Founded 2021